EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research

Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma
CONCLUSION: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.PMID:38059173 | PMC:PMC10695748 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Zhangfu Li Jiangbei Yuan Zilong Yan Xu Liu Jikui Liu Source Type: research

Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. eCollection 2023.ABSTRACTLenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant s...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Xinlin Yu Chun Wei Ran Cui Ou Jiang Source Type: research

Bilateral and synchronous male breast cancer: a case report
Int J Clin Exp Pathol. 2023 Nov 15;16(11):352-356. eCollection 2023.ABSTRACTGenetic mutational characterization of synchronous bilateral male breast cancer (BC) has been poorly reported due to its rarity. Herein, we present a 55-year-old male patient who was diagnosed with bilateral breast cancer (BBC) and harbored different gene mutations. The diagnosis of synchronous bilateral breast cancer (SBBC) was made using ultrasonography, magnetic resonance imaging (MRI), mammography and core-needle biopsy. Subsequently, bilateral modified radical mastectomies were performed, and histopathologic examination revealed invasive ducta...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Shaoqiang Zhou Jiankui Wang Ming Li Yinju Yang Hushan Zhang Dedian Chen Source Type: research

Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research

EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research

Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma
CONCLUSION: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.PMID:38059173 | PMC:PMC10695748 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Zhangfu Li Jiangbei Yuan Zilong Yan Xu Liu Jikui Liu Source Type: research

Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. eCollection 2023.ABSTRACTLenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant s...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Xinlin Yu Chun Wei Ran Cui Ou Jiang Source Type: research

Bilateral and synchronous male breast cancer: a case report
Int J Clin Exp Pathol. 2023 Nov 15;16(11):352-356. eCollection 2023.ABSTRACTGenetic mutational characterization of synchronous bilateral male breast cancer (BC) has been poorly reported due to its rarity. Herein, we present a 55-year-old male patient who was diagnosed with bilateral breast cancer (BBC) and harbored different gene mutations. The diagnosis of synchronous bilateral breast cancer (SBBC) was made using ultrasonography, magnetic resonance imaging (MRI), mammography and core-needle biopsy. Subsequently, bilateral modified radical mastectomies were performed, and histopathologic examination revealed invasive ducta...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Shaoqiang Zhou Jiankui Wang Ming Li Yinju Yang Hushan Zhang Dedian Chen Source Type: research

Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research

EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research

Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma
CONCLUSION: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.PMID:38059173 | PMC:PMC10695748 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Zhangfu Li Jiangbei Yuan Zilong Yan Xu Liu Jikui Liu Source Type: research

Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. eCollection 2023.ABSTRACTLenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant s...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Xinlin Yu Chun Wei Ran Cui Ou Jiang Source Type: research

Bilateral and synchronous male breast cancer: a case report
Int J Clin Exp Pathol. 2023 Nov 15;16(11):352-356. eCollection 2023.ABSTRACTGenetic mutational characterization of synchronous bilateral male breast cancer (BC) has been poorly reported due to its rarity. Herein, we present a 55-year-old male patient who was diagnosed with bilateral breast cancer (BBC) and harbored different gene mutations. The diagnosis of synchronous bilateral breast cancer (SBBC) was made using ultrasonography, magnetic resonance imaging (MRI), mammography and core-needle biopsy. Subsequently, bilateral modified radical mastectomies were performed, and histopathologic examination revealed invasive ducta...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Shaoqiang Zhou Jiankui Wang Ming Li Yinju Yang Hushan Zhang Dedian Chen Source Type: research

Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research